Department of Otolaryngology, Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai, China.
Department of Ophthalmology, Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai, China.
Head Neck. 2021 Jun;43(6):1769-1779. doi: 10.1002/hed.26641. Epub 2021 Feb 15.
Minor salivary gland cancer (MiSGC) is a group of tumors with varied disease course in the head and neck. We evaluated the risk of a second primary malignancy (SPM) in MiSGC patients and identified possible prognostic factors for survival using a large population database.
We used the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) data to evaluate the risk and prognosis of SPM in patients diagnosed with MiSGC.
The risk of SPM increased in MiSGC patients compared with the endemic rate. The risk of SPM was slightly greater in female patients and who underwent radiotherapy. Age at primary diagnosis, sex, race, year of diagnosis, SEER stage, radiotherapy, SPM, histology, and tumor site were significant survival prognostic indicators of MiSGC patients.
Radiotherapy and female sex were risk factors for SPM after MiSGC. Long-term surveillance for SPM was important in MiSGC patients.
小唾液腺癌（MiSGC）是一组头颈部疾病病程多样的肿瘤。我们使用大型人群数据库评估 MiSGC 患者发生第二原发恶性肿瘤（SPM）的风险，并确定可能影响生存的预后因素。
我们使用美国国家癌症研究所的监测、流行病学和最终结果（SEER）数据评估 MiSGC 患者诊断后 SPM 的风险和预后。
与本底率相比，MiSGC 患者 SPM 的发病风险增加。女性患者和接受放射治疗的患者 SPM 发病风险略高。MiSGC 患者的生存预后指标包括年龄、性别、种族、诊断年份、SEER 分期、放疗、SPM、组织学和肿瘤部位。
MiSGC 后放疗和女性是 SPM 的危险因素。MiSGC 患者需要长期监测 SPM。
